Humacyte, Inc. (HUMA)
Price:
1.58 USD
( + 0.04 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
NEWS
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
zacks.com
2025-08-20 10:31:13The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
seekingalpha.com
2025-08-12 13:20:47I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles highlight significant barriers to broader commercial success. In my opinion, HUMA's cash runway extends only into early 2026, with ongoing dilution and a likely need for additional financing soon.
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-11 10:00:54Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-11 09:16:13Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
2025-08-11 07:00:00- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals - - Conference call today at 8:00 am ET - DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
globenewswire.com
2025-08-07 08:00:00DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
zacks.com
2025-08-06 19:01:36Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
zacks.com
2025-07-31 19:01:48Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
zacks.com
2025-07-25 19:01:30Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com
2025-07-24 19:16:06Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
globenewswire.com
2025-07-23 08:00:00Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility.
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
zacks.com
2025-07-15 19:15:31Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
zacks.com
2025-07-09 19:16:29The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
globenewswire.com
2025-07-08 08:00:00DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
zacks.com
2025-06-30 19:00:19The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.
Humacyte: Revenue Ramp From Symvess Incoming
seekingalpha.com
2025-06-11 09:05:31Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.
No data to display
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
zacks.com
2025-08-20 10:31:13The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
seekingalpha.com
2025-08-12 13:20:47I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles highlight significant barriers to broader commercial success. In my opinion, HUMA's cash runway extends only into early 2026, with ongoing dilution and a likely need for additional financing soon.
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-11 10:00:54Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-11 09:16:13Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
2025-08-11 07:00:00- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals - - Conference call today at 8:00 am ET - DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
globenewswire.com
2025-08-07 08:00:00DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
zacks.com
2025-08-06 19:01:36Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
zacks.com
2025-07-31 19:01:48Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
zacks.com
2025-07-25 19:01:30Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com
2025-07-24 19:16:06Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
globenewswire.com
2025-07-23 08:00:00Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility.
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
zacks.com
2025-07-15 19:15:31Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
zacks.com
2025-07-09 19:16:29The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
globenewswire.com
2025-07-08 08:00:00DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
zacks.com
2025-06-30 19:00:19The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.
Humacyte: Revenue Ramp From Symvess Incoming
seekingalpha.com
2025-06-11 09:05:31Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.